Chimeric antigen receptor T-cell therapy:a promising treatment modality for relapsed/refractory mant

• 作 者: Ping Li Ningxin Dong Yu Zeng Jie Liu Xiaochen Tang Junbang Wang Wenjun Zhang Shiguang Ye Lili Zhou Alex Hongsheng Chang Aibin Liang
• 机 构: Department of Hematology, Tongji Hospital of Tongji University School of Medicine, Shanghai 200065,
• 出 处: 医学前沿
• 发表日期: 2020年6期
• 关键词: anti-CD19 chimeric antigen receptor T cells mantle cell lymphoma relapsed or ref

Mantle cell lymphoma (MCL) is a distinct histological type of B-cell lymphoma with a poor prognosis.Several agents,such as proteasome inhibitors,immunomodulatory drugs,and inhibitors of B cell lymphoma-2 and Bruton's tyrosine kinase have shown efficacy for relapsed or refractory (r/r) MCL but often have short-term responses.Chimeric antigen receptor (CAR) T-cell therapy has emerged as a novel treatment modality for r/r non-Hodgkin's lymphoma.However,long-term safety and tolerability associated with CAR T-cell therapy are not defined well,especially in MCL.In this report,we described a 70-year-old patient with r/r MCL with 48-month duration of follow-up who achieved long-term remission after CAR T-cell therapy.CAR T-cell-related toxicities were also mild and tolerated well even in this elderly patient.This report suggested that CAR T-cell therapy is a promising treatment modality for patients with MCL,who are generally elderly and have comorbid conditions.